STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Equillium to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Equillium (Nasdaq: EQ) announced management will participate in two investor conferences in early December 2025: the Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 11:30 AM ET and the Evercore ISI 8th Annual Healthcare Conference on Dec 3, 2025 at 3:50 PM ET. Meetings will include fireside chats and 1x1 investor meetings.

Management is available for meetings with registered investors. Investors are invited to review the company corporate deck on the Events & Presentations page and the replay of the recent virtual KOL event discussing EQ504, an aryl hydrocarbon receptor modulator for ulcerative colitis.

Equillium (Nasdaq: EQ) ha annunciato che la direzione parteciperà a due conferenze per investitori all'inizio di dicembre 2025: la Piper Sandler 37th Annual Healthcare Conference il 2 dicembre 2025 alle 11:30 AM ET e la Evercore ISI 8th Annual Healthcare Conference il 3 dicembre 2025 alle 3:50 PM ET. Gli incontri comprenderanno chiacchierate davanti al fuoco e incontri 1x1 con investitori.

La direzione è disponibile per incontri con investitori registrati. Gli investitori sono invitati a consultare la presentazione aziendale sulla pagina Events & Presentations e la replica dell'ultimo evento virtuale KOL che discute EQ504, un modulatore del recettore arilidrocarbonico per la colite ulcerosa.

Equillium (Nasdaq: EQ) anunció que la dirección participará en dos conferencias para inversores a principios de diciembre de 2025: la Piper Sandler 37th Annual Healthcare Conference el 2 de diciembre de 2025 a las 11:30 AM ET y la Evercore ISI 8th Annual Healthcare Conference el 3 de diciembre de 2025 a las 3:50 PM ET. Las reuniones incluirán charlas junto a la chimenea y reuniones 1x1 con inversores.

La dirección está disponible para reuniones con inversores registrados. Se invita a los inversores a revisar la presentación corporativa en la página Events & Presentations y la reproducción del reciente evento virtual de KOL que discute EQ504, un modulador del receptor de hidrocarburos arílicos para la colitis ulcerosa.

Equillium (Nasdaq: EQ)의 경영진은 2025년 12월 초에 두 차례의 투자자 컨퍼런스에 참여할 예정이라고 발표했습니다: Piper Sandler 37th Annual Healthcare Conference2025년 12월 2일 11:30 AM ET에, Evercore ISI 8th Annual Healthcare Conference2025년 12월 3일 3:50 PM ET에 열립니다. 회의에는 파이어사이드 채팅과 1대1 투자자 미팅이 포함될 것입니다.

등록된 투자자와의 회의가 경영진의 이용 가능 대상입니다. 투자자들은 Events & Presentations 페이지의 회사 프레젠테이션과 EQ504를 다루는 최근 가상 KOL 이벤트의 재생을 검토하길 권장합니다. EQ504는 궤 양성 부위인 안과 위산 보호를 위한 아릴 하이드로카본 수용체 조절제입니다.

Equillium (Nasdaq: EQ) a annoncé que la direction participera à deux conférences investisseurs début décembre 2025 : la Piper Sandler 37th Annual Healthcare Conference le 2 décembre 2025 à 11h30 ET et la Evercore ISI 8th Annual Healthcare Conference le 3 décembre 2025 à 15h50 ET. Les rencontres comprendront des chats au coin du feu et des entretiens individuels avec les investisseurs.

La direction est disponible pour des réunions avec les investisseurs enregistrés. Les investisseurs sont invités à consulter le deck corporatif sur la page Events & Presentations et la rediffusion du récent événement virtuel KOL qui discute EQ504, un modulateur du récepteur aryl hydrocarbonique pour la colite ulcéreuse.

Equillium (Nasdaq: EQ) gab bekannt, dass das Management an zwei Investorenkonferenzen Anfang Dezember 2025 teilnehmen wird: die Piper Sandler 37th Annual Healthcare Conference am 2. Dezember 2025 um 11:30 Uhr ET und die Evercore ISI 8th Annual Healthcare Conference am 3. Dezember 2025 um 15:50 Uhr ET. Meetings werden Fireside Chats und 1x1-Investorengespräche umfassen.

Das Management steht registrierten Investoren für Meetings zur Verfügung. Investoren sind eingeladen, sich das Unternehmensdeck auf der Seite Events & Presentations anzusehen und die Wiederholung der jüngsten virtuellen KOL-Veranstaltung zu EQ504 zu prüfen, einem Modulator des aryl-hydrocarbon-Receptors für Colitis ulcerosa.

Equillium (Nasdaq: EQ) أعلنت الإدارة أنها ستشارك في مؤتمرين للمستثمرين في أوائل ديسمبر 2025: Piper Sandler 37th Annual Healthcare Conference في 2 ديسمبر 2025 الساعة 11:30 صباحاً بتوقيت شرق الولايات المتحدة وEvercore ISI 8th Annual Healthcare Conference في 3 ديسمبر 2025 الساعة 3:50 مساءً بتوقيت شرق الولايات المتحدة. ستشمل الاجتماعات محادثات Fireside واجتماعات ثنائية مع المستثمرين.

الإدارة متاحة للاجتماعات مع المستثمرين المسجلين. يُدعى المستثمرون للاطلاع على عرض الشركة على صفحة Events & Presentations وللاطلاع على إعادة عرض الحدث الافتراضي الأخير لـ KOL الذي يناقش EQ504، وهو مُعَدل مستقبل لمستقبل مستقبل مستقبل لمستقبل الهيدروكاربن المرتبط بالتهاب القولون التقرحي.

Positive
  • None.
Negative
  • None.

LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:

Piper Sandler 37th Annual Healthcare Conference
Format:Fireside Chat & 1x1 Meetings
Date:Tuesday, December 2, 2025
Time:11:30 AM EST


Evercore ISI 8th Annual Healthcare Conference
Format:Fireside Chat & 1x1 Meetings
Date:Wednesday, December 3, 2025
Time:3:50 PM EST


Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.

Investors are invited to review the company corporate deck found on the Events & Presentations page, as well as the replay from the recent virtual KOL Event to discuss EQ504: A Novel Aryl Hydrocarbon Receptor (AhR) Modulator for Ulcerative Colitis.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. 

For more information, visit www.equilliumbio.com.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com


FAQ

When will Equillium (EQ) present at the Piper Sandler Healthcare Conference?

Equillium management will present on December 2, 2025 at 11:30 AM ET with a fireside chat and 1x1 meetings.

When is Equillium (EQ) scheduled to participate at the Evercore ISI Healthcare Conference?

Equillium management will participate on December 3, 2025 at 3:50 PM ET including a fireside chat and 1x1 meetings.

How can investors request meetings with Equillium (EQ) at these conferences?

Investors registered for the conferences can request meetings directly with Equillium management; availability is for registered attendees only.

Where can investors find Equillium's (EQ) corporate deck and related materials ahead of the conferences?

The corporate deck is available on the company's Events & Presentations page on its investor website.

What recent program will Equillium (EQ) discuss in the conference materials and replay?

The company provided a replay of a virtual KOL event discussing EQ504, an AhR modulator under development for ulcerative colitis.
Equillium

NASDAQ:EQ

EQ Rankings

EQ Latest News

EQ Latest SEC Filings

EQ Stock Data

61.50M
48.01M
21.55%
11.74%
3.44%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA